Mouse anti-Human CD105 Antibody | anti-CD105 antibody

Mouse Anti-Human CD105-FITC

Cat. Num. AAA679326

• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay, Immunohistochemistry, Immunocytochemistry, Immunoprecipitation, Immunoblot, Western Blot
• Synonyms: CD105; Mouse Anti-Human CD105-FITC; Endoglin; anti-CD105 antibody

• Host: Mouse
• Reactivity: Human
• Isotype: IgG1kappa
• Clone Number: SN6
• Specificity: Human CD105
• Form/Format: Supplied in PBS/NaN3

• Applicable Applications for anti-CD105 antibody: Flow Cytometry (FC/FACS), Immunohistochemistry (IHC) Formalin/Paraffin, Immunocytochemistry (ICC), Immunoprecipitation (IP), Immunoblotting (IB), Purification
• Volume: 1.0 mL
• Immunogen: Antigen preparation isolated from cell membranes of leukemia cells derived from a patient with non-T/non-B-cell acute lymphoblastic leukemia (ALL)
• Conjugate: FITC (Fluorescein)
• Isotype Control: Mouse IgG1-FITC
• Preparation and Storage: Store at 2-8 degree C.

Testing Data

Related Product Information for anti-CD105 antibody

CD105, also known as endoglin, is a 90 kDa type II transmembrane glycoprotein that is expressed on the cell surface as a disulfide-linked homodimer and is found on endothelial cells. CD105 is one of several receptors for the various isoforms of TGF? which in turn is one of a family of proteins involved in regulation of cell differentiation, migration of cells, and control on the immune response.

References

1. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA. 1986;83:7898-902. (Immunogen, IP). 2. Toi H, Tsujie M, Haruta Y, Fujita K, Duzen J, Seon BK. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105). Int J Cancer. 2014 May 28. doi: 10.1002/ijc.28994. [Epub ahead of print] (IHC-FS). 3. Chung Y, Hou Y, Pan AC. Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest. 2004;34:107-112. (IHC-PS). 4. Meng Q, Lux A, Holloschi A, Li J, Hughes JM, Foerg T, et al. Identification of Tctex2beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. J Biol Chem. 2006;281:37069-80. (ICC). 5. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524-32. (IP). 6. Shinojima N, Hossain A, Takezaki T, Fueyo J, Gumin J, Gao F, et al. TGF-beta mediates homing of bone marrow-derived human mesenchymal stem cells to glioma stem cells. Cancer Res. 2012;73:2333-44. (WB). 7. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res. 1997;3:1031-44. (IP, Purification). 8. Røsland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69:5331-9. (FC). 9. Guasti L, Prasongchean W, Kleftouris G, Mukherjee S, Thrasher AJ, Bulstrode NW, et al. High plasticity of pediatric adipose tissue-derived stem cells: too much for selective skeletogenic differentiation?. Stem Cells Transl Med. 2012;1:384-95. (FC). 10. Schmitt A, Ehnert S, Schyschka L, Buschner P, Kühnl A, Döbele S, et al. Monocytes do not transdifferentiate into proper osteoblasts. ScientificWorldJournal. 2012;2012:384936. (FC)